Skip to content

TriangleGet started

← Full study record

NCT04162210 · OUTCOME

Change From Baseline (CFB) in Ocular Surface Disease Index (OSDI) Total Score

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · Source last updated 2026-07-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: Scores on Scale
Interval / dispersion: Standard Deviation
Time frame: Baseline (Day 1) and Up to approximately 263 weeks

What was measured

OSDI is 12-item patient-reported outcomes questionnaire designed to provide rapid assessment of range of ocular surface symptoms, including symptoms related to chronic dry eye, severity, and impact on patient's ability to function. In addition to an overall score, there are three subscales of OSDI: ocular symptoms, vision-related function, and environmental triggers. OSDI items are scored on a 0 to 4 Likert-type scale, where 0 = None of the time and 4 = All of the time. Total OSDI score = (\[sum of scores for all questions answered×100\]/\[total number of questions answered×4\]). Subscale scores are computed similarly with only questions from each subscale used to generate its own score. Any subscales analyzed separately would also have a maximum possible score of 100. A score of 100=to complete disability, while a score of 0=to no disability. Decrease in score from baseline means improvement

Analysis population: Safety Population. Only participants with data available at specific timepoints have been analyzed.

Groups in this outcome

Belantamab Mafodotin

Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle

Pomalidomide Plus Dexamethasone

Participants with RRMM received 4 mg pomalidomide capsule daily on Days 1 to 21 of each 28-day cycle, along with 40 mg or at lower 20 mg (for participants \>75 years of age) dose of dexamethasone tablet once weekly (Days 1, 8, 15 and 22)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	217
Pomalidomide Plus Dexamethasone	102

Reported measurements

CFB to Week 4

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	168
Pomalidomide Plus Dexamethasone	77

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	2.59	17.476	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	1.41	12.547	Not reported	Not reported	Not reported

CFB to Week 7

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	140
Pomalidomide Plus Dexamethasone	74

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	13.07	25.989	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	1.66	14.990	Not reported	Not reported	Not reported

CFB to Week 10

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	128
Pomalidomide Plus Dexamethasone	63

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	15.29	27.843	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	2.66	19.075	Not reported	Not reported	Not reported

CFB to Week 13

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	110
Pomalidomide Plus Dexamethasone	57

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	13.38	26.089	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	4.19	16.918	Not reported	Not reported	Not reported

CFB to Week 16

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	103
Pomalidomide Plus Dexamethasone	53

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	13.26	26.184	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	3.11	18.073	Not reported	Not reported	Not reported

CFB to Week 19

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	96
Pomalidomide Plus Dexamethasone	48

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	10.80	26.948	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	3.40	20.072	Not reported	Not reported	Not reported

CFB to Week 22

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	95
Pomalidomide Plus Dexamethasone	40

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	11.90	25.844	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	5.07	20.162	Not reported	Not reported	Not reported

CFB to Week 25

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	90
Pomalidomide Plus Dexamethasone	34

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	10.80	22.411	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	3.04	15.127	Not reported	Not reported	Not reported

CFB to Week 28

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	84
Pomalidomide Plus Dexamethasone	35

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	10.00	24.292	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	2.42	16.637	Not reported	Not reported	Not reported

CFB to Week 31

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	77
Pomalidomide Plus Dexamethasone	33

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	11.59	24.217	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	0.10	14.473	Not reported	Not reported	Not reported

CFB to Week 34

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	73
Pomalidomide Plus Dexamethasone	25

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	12.78	24.293	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-3.77	16.175	Not reported	Not reported	Not reported

CFB to Week 37

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	69
Pomalidomide Plus Dexamethasone	25

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	11.12	25.434	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-4.01	13.960	Not reported	Not reported	Not reported

CFB to Week 40

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	69
Pomalidomide Plus Dexamethasone	25

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	11.94	29.680	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	6.25	30.021	Not reported	Not reported	Not reported

CFB to Week 43

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	69
Pomalidomide Plus Dexamethasone	21

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	9.94	26.511	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-2.57	13.078	Not reported	Not reported	Not reported

CFB to Week 46

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	63
Pomalidomide Plus Dexamethasone	16

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	13.39	23.682	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-1.05	10.973	Not reported	Not reported	Not reported

CFB to Week 49

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	64
Pomalidomide Plus Dexamethasone	19

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	9.43	23.900	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-1.58	10.344	Not reported	Not reported	Not reported

CFB to Week 52

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	63
Pomalidomide Plus Dexamethasone	20

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	8.50	23.103	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-3.39	11.210	Not reported	Not reported	Not reported

CFB to Week 55

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	60
Pomalidomide Plus Dexamethasone	19

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	6.71	23.217	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-2.40	11.789	Not reported	Not reported	Not reported

CFB to Week 58

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	56
Pomalidomide Plus Dexamethasone	18

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	8.06	27.288	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-1.71	11.305	Not reported	Not reported	Not reported

CFB to Week 61

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	52
Pomalidomide Plus Dexamethasone	18

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	9.86	24.993	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-1.46	13.508	Not reported	Not reported	Not reported

CFB to Week 64

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	51
Pomalidomide Plus Dexamethasone	15

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	11.15	27.558	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-0.90	11.579	Not reported	Not reported	Not reported

CFB to Week 67

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	50
Pomalidomide Plus Dexamethasone	16

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	8.72	25.841	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-1.08	12.042	Not reported	Not reported	Not reported

CFB to Week 70

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	49
Pomalidomide Plus Dexamethasone	13

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	5.82	25.580	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	2.21	7.068	Not reported	Not reported	Not reported

CFB to Week 73

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	41
Pomalidomide Plus Dexamethasone	15

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	10.00	27.506	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	0.42	12.045	Not reported	Not reported	Not reported

CFB to Week 76

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	42
Pomalidomide Plus Dexamethasone	15

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	13.64	25.404	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	4.93	10.105	Not reported	Not reported	Not reported

CFB to Week 79

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	42
Pomalidomide Plus Dexamethasone	15

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	11.45	29.293	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	0.33	10.061	Not reported	Not reported	Not reported

CFB to Week 82

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	43
Pomalidomide Plus Dexamethasone	15

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	7.54	27.703	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-1.60	10.799	Not reported	Not reported	Not reported

CFB to Week 85

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	37
Pomalidomide Plus Dexamethasone	13

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	9.21	30.044	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-1.45	14.926	Not reported	Not reported	Not reported

CFB to Week 88

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	36
Pomalidomide Plus Dexamethasone	13

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	8.16	29.508	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-1.09	12.537	Not reported	Not reported	Not reported

CFB to Week 91

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	36
Pomalidomide Plus Dexamethasone	13

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	14.39	35.202	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-1.40	15.058	Not reported	Not reported	Not reported

CFB to Week 94

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	36
Pomalidomide Plus Dexamethasone	12

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	7.34	28.796	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-1.92	17.782	Not reported	Not reported	Not reported

CFB to Week 97

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	30
Pomalidomide Plus Dexamethasone	11

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	12.80	19.992	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	0.98	15.164	Not reported	Not reported	Not reported

CFB to Week 100

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	35
Pomalidomide Plus Dexamethasone	10

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	11.67	28.130	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	1.21	14.782	Not reported	Not reported	Not reported

CFB to Week 103

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	34
Pomalidomide Plus Dexamethasone	9

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	7.19	26.707	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-0.09	18.537	Not reported	Not reported	Not reported

CFB to Week 106

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	33
Pomalidomide Plus Dexamethasone	6

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	5.40	26.244	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-0.90	20.060	Not reported	Not reported	Not reported

CFB to Week 109

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	34
Pomalidomide Plus Dexamethasone	8

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	4.79	25.159	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	3.11	15.098	Not reported	Not reported	Not reported

CFB to Week 112

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	30
Pomalidomide Plus Dexamethasone	7

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	3.31	23.345	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-0.70	18.898	Not reported	Not reported	Not reported

CFB to Week 115

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	30
Pomalidomide Plus Dexamethasone	8

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	3.20	23.763	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	5.18	14.995	Not reported	Not reported	Not reported

CFB to Week 118

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	30
Pomalidomide Plus Dexamethasone	8

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	6.93	28.876	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	3.78	22.276	Not reported	Not reported	Not reported

CFB to Week 121

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	25
Pomalidomide Plus Dexamethasone	8

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	4.59	30.664	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	0.83	21.583	Not reported	Not reported	Not reported

CFB to Week 124

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	26
Pomalidomide Plus Dexamethasone	6

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	6.22	30.072	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	2.71	25.931	Not reported	Not reported	Not reported

CFB to Week 127

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	26
Pomalidomide Plus Dexamethasone	6

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.62	27.862	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	3.59	20.142	Not reported	Not reported	Not reported

CFB to Week 130

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	25
Pomalidomide Plus Dexamethasone	5

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-0.38	26.198	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-0.76	26.377	Not reported	Not reported	Not reported

CFB to Week 133

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	24
Pomalidomide Plus Dexamethasone	6

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	4.17	31.724	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	3.31	27.578	Not reported	Not reported	Not reported

CFB to Week 136

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	21
Pomalidomide Plus Dexamethasone	5

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	4.67	30.314	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-1.76	28.117	Not reported	Not reported	Not reported

CFB to Week 139

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	20
Pomalidomide Plus Dexamethasone	6

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	12.31	24.985	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	0.47	26.057	Not reported	Not reported	Not reported

CFB to Week 142

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	22
Pomalidomide Plus Dexamethasone	4

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	1.71	28.995	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-0.21	37.083	Not reported	Not reported	Not reported

CFB to Week 145

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	18
Pomalidomide Plus Dexamethasone	5

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	10.39	20.291	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-4.03	25.715	Not reported	Not reported	Not reported

CFB to Week 151

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	21
Pomalidomide Plus Dexamethasone	4

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	6.42	29.284	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-0.25	30.276	Not reported	Not reported	Not reported

CFB to Week 154

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	18
Pomalidomide Plus Dexamethasone	4

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	5.96	31.273	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	0.93	28.401	Not reported	Not reported	Not reported

CFB to Week 157

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	17
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	1.62	30.352	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-5.42	35.933	Not reported	Not reported	Not reported

CFB to Week 160

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	18
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	5.59	34.252	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-7.85	32.500	Not reported	Not reported	Not reported

CFB to Week 163

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	18
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	2.02	31.500	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-1.94	42.950	Not reported	Not reported	Not reported

CFB to Week 166

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	15
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	7.78	12.660	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	3.89	29.360	Not reported	Not reported	Not reported

CFB to Week 169

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	17
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	2.43	32.178	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-2.78	39.240	Not reported	Not reported	Not reported

CFB to Week 172

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	13
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-5.88	33.448	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-11.57	30.185	Not reported	Not reported	Not reported

CFB to Week 175

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	12
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	6.06	19.269	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	5.28	37.364	Not reported	Not reported	Not reported

CFB to Week 178

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	14
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	2.83	41.101	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	1.62	30.108	Not reported	Not reported	Not reported

CFB to Week 181

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	14
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-6.07	32.570	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	1.99	42.043	Not reported	Not reported	Not reported

CFB to Week 184

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	11
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-1.11	44.766	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	0.19	32.223	Not reported	Not reported	Not reported

CFB to Week 187

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	9
Pomalidomide Plus Dexamethasone	2

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.73	16.111	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	43.33	15.321	Not reported	Not reported	Not reported

CFB to Week 193

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	7
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-16.07	43.956	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	4.93	37.846	Not reported	Not reported	Not reported

CFB to Week 196

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	9
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-9.58	38.655	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	9.44	44.098	Not reported	Not reported	Not reported

CFB to Week 199

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	5
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-6.96	20.187	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-5.97	23.810	Not reported	Not reported	Not reported

CFB to Week 202

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	8
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-11.72	40.286	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	-3.01	9.857	Not reported	Not reported	Not reported

CFB to Week 208

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	7
Pomalidomide Plus Dexamethasone	2

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-14.13	40.965	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	11.25	15.910	Not reported	Not reported	Not reported

CFB to Week 211

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	5
Pomalidomide Plus Dexamethasone	2

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-19.11	47.990	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	8.75	12.374	Not reported	Not reported	Not reported

CFB to Week 214

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	3
Pomalidomide Plus Dexamethasone	2

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	13.61	16.881	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	5.00	7.071	Not reported	Not reported	Not reported

CFB to Week 217

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	2
Pomalidomide Plus Dexamethasone	2

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-48.96	69.238	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	7.50	10.607	Not reported	Not reported	Not reported

CFB to Week 220

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	2
Pomalidomide Plus Dexamethasone	2

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-9.29	17.071	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	11.11	15.713	Not reported	Not reported	Not reported

CFB to Week 223

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	4
Pomalidomide Plus Dexamethasone	2

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-31.84	47.569	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	8.75	12.374	Not reported	Not reported	Not reported

CFB to Week 226

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	3
Pomalidomide Plus Dexamethasone	1

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-42.79	50.110	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	7.50	NA	Not reported	Not reported	Standard Deviation is not evaluable for a single participant.

CFB to Week 229

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	2
Pomalidomide Plus Dexamethasone	1

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-14.38	20.329	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	15.00	NA	Not reported	Not reported	Standard Deviation is not evaluable for a single participant.

CFB to Week 232

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	3
Pomalidomide Plus Dexamethasone	1

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-42.10	48.966	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	10.00	NA	Not reported	Not reported	Standard Deviation is not evaluable for a single participant.

CFB to Week 235

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	2
Pomalidomide Plus Dexamethasone	1

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	-50.00	70.711	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	20.00	NA	Not reported	Not reported	Standard Deviation is not evaluable for a single participant.

CFB to Week 238

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	0
Pomalidomide Plus Dexamethasone	1

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Pomalidomide Plus Dexamethasone	15.00	NA	Not reported	Not reported	Standard Deviation is not evaluable for a single participant.

CFB to LFU (~263 weeks)

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	52
Pomalidomide Plus Dexamethasone	3

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	2.81	21.245	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	15.74	9.755	Not reported	Not reported	Not reported

CFB to EOT (~242 weeks)

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	118
Pomalidomide Plus Dexamethasone	64

Values in Scores on Scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	11.77	25.264	Not reported	Not reported	Not reported
Pomalidomide Plus Dexamethasone	6.08	18.132	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
17.476
value
2.59
group Id
OG001
spread
12.547
value
1.41
denoms
counts
group Id
OG000
value
168
group Id
OG001
value
77
units
Participants
title
CFB to Week 4
categories
measurements
group Id
OG000
spread
25.989
value
13.07
group Id
OG001
spread
14.990
value
1.66
denoms
counts
group Id
OG000
value
140
group Id
OG001
value
74
units
Participants
title
CFB to Week 7
categories
measurements
group Id
OG000
spread
27.843
value
15.29
group Id
OG001
spread
19.075
value
2.66
denoms
counts
group Id
OG000
value
128
group Id
OG001
value
63
units
Participants
title
CFB to Week 10
categories
measurements
group Id
OG000
spread
26.089
value
13.38
group Id
OG001
spread
16.918
value
4.19
denoms
counts
group Id
OG000
value
110
group Id
OG001
value
57
units
Participants
title
CFB to Week 13
categories
measurements
group Id
OG000
spread
26.184
value
13.26
group Id
OG001
spread
18.073
value
3.11
denoms
counts
group Id
OG000
value
103
group Id
OG001
value
53
units
Participants
title
CFB to Week 16
categories
measurements
group Id
OG000
spread
26.948
value
10.80
group Id
OG001
spread
20.072
value
3.40
denoms
counts
group Id
OG000
value
96
group Id
OG001
value
48
units
Participants
title
CFB to Week 19
categories
measurements
group Id
OG000
spread
25.844
value
11.90
group Id
OG001
spread
20.162
value
5.07
denoms
counts
group Id
OG000
value
95
group Id
OG001
value
40
units
Participants
title
CFB to Week 22
categories
measurements
group Id
OG000
spread
22.411
value
10.80
group Id
OG001
spread
15.127
value
3.04
denoms
counts
group Id
OG000
value
90
group Id
OG001
value
34
units
Participants
title
CFB to Week 25
categories
measurements
group Id
OG000
spread
24.292
value
10.00
group Id
OG001
spread
16.637
value
2.42
denoms
counts
group Id
OG000
value
84
group Id
OG001
value
35
units
Participants
title
CFB to Week 28
categories
measurements
group Id
OG000
spread
24.217
value
11.59
group Id
OG001
spread
14.473
value
0.10
denoms
counts
group Id
OG000
value
77
group Id
OG001
value
33
units
Participants
title
CFB to Week 31
categories
measurements
group Id
OG000
spread
24.293
value
12.78
group Id
OG001
spread
16.175
value
-3.77
denoms
counts
group Id
OG000
value
73
group Id
OG001
value
25
units
Participants
title
CFB to Week 34
categories
measurements
group Id
OG000
spread
25.434
value
11.12
group Id
OG001
spread
13.960
value
-4.01
denoms
counts
group Id
OG000
value
69
group Id
OG001
value
25
units
Participants
title
CFB to Week 37

denoms

counts
group Id
OG000
value
217
group Id
OG001
value
102
units
Participants

description

OSDI is 12-item patient-reported outcomes questionnaire designed to provide rapid assessment of range of ocular surface symptoms, including symptoms related to chronic dry eye, severity, and impact on patient's ability to function. In addition to an overall score, there are three subscales of OSDI: ocular symptoms, vision-related function, and environmental triggers. OSDI items are scored on a 0 to 4 Likert-type scale, where 0 = None of the time and 4 = All of the time. Total OSDI score = (\[sum of scores for all questions answered×100\]/\[total number of questions answered×4\]). Subscale scores are computed similarly with only questions from each subscale used to generate its own score. Any subscales analyzed separately would also have a maximum possible score of 100. A score of 100=to complete disability, while a score of 0=to no disability. Decrease in score from baseline means improvement

dispersion Type

Standard Deviation

groups

description
Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle
id
OG000
title
Belantamab Mafodotin
description
Participants with RRMM received 4 mg pomalidomide capsule daily on Days 1 to 21 of each 28-day cycle, along with 40 mg or at lower 20 mg (for participants \>75 years of age) dose of dexamethasone tablet once weekly (Days 1, 8, 15 and 22)
id
OG001
title
Pomalidomide Plus Dexamethasone

param Type

MEAN

population Description

Safety Population. Only participants with data available at specific timepoints have been analyzed.

reporting Status

POSTED

time Frame

Baseline (Day 1) and Up to approximately 263 weeks

title

Change From Baseline (CFB) in Ocular Surface Disease Index (OSDI) Total Score

type

SECONDARY

unit Of Measure

Scores on Scale

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice